184 related articles for article (PubMed ID: 17513288)
41. Newborn screening for medium chain acyl-CoA dehydrogenase deficiency in England: prevalence, predictive value and test validity based on 1.5 million screened babies.
Oerton J; Khalid JM; Besley G; Dalton RN; Downing M; Green A; Henderson M; Krywawych S; Leonard J; Andresen BS; Dezateux C
J Med Screen; 2011; 18(4):173-81. PubMed ID: 22166308
[TBL] [Abstract][Full Text] [Related]
42. Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program.
Zytkovicz TH; Fitzgerald EF; Marsden D; Larson CA; Shih VE; Johnson DM; Strauss AW; Comeau AM; Eaton RB; Grady GF
Clin Chem; 2001 Nov; 47(11):1945-55. PubMed ID: 11673361
[TBL] [Abstract][Full Text] [Related]
43. Blood acylcarnitine levels in normal newborns and heterozygotes for medium-chain acyl-CoA dehydrogenase deficiency: a relationship between genotype and biochemical phenotype?
Lehotay DC; LePage J; Thompson JR; Rockman-Greenberg C
J Inherit Metab Dis; 2004; 27(1):81-8. PubMed ID: 14970748
[TBL] [Abstract][Full Text] [Related]
44. Selective screening for inborn errors of metabolism on clinical patients using tandem mass spectrometry in China: a four-year report.
Han LS; Ye J; Qiu WJ; Gao XL; Wang Y; Gu XF
J Inherit Metab Dis; 2007 Aug; 30(4):507-14. PubMed ID: 17347912
[TBL] [Abstract][Full Text] [Related]
45. Differences between acylcarnitine profiles in plasma and bloodspots.
de Sain-van der Velden MG; Diekman EF; Jans JJ; van der Ham M; Prinsen BH; Visser G; Verhoeven-Duif NM
Mol Genet Metab; 2013; 110(1-2):116-21. PubMed ID: 23639448
[TBL] [Abstract][Full Text] [Related]
46. Expanded newborn screening: outcome in screened and unscreened patients at age 6 years.
Wilcken B; Haas M; Joy P; Wiley V; Bowling F; Carpenter K; Christodoulou J; Cowley D; Ellaway C; Fletcher J; Kirk EP; Lewis B; McGill J; Peters H; Pitt J; Ranieri E; Yaplito-Lee J; Boneh A
Pediatrics; 2009 Aug; 124(2):e241-8. PubMed ID: 19620191
[TBL] [Abstract][Full Text] [Related]
47. [Clinical, biochemical and gene mutation characteristics of short chain acyl-coenzyme A dehydrogenase deficiency by neonatal screening].
Huang XW; Zhang Y; Yang JB; Hong F; Qian GL; Tong F; Mao HQ; Huang XL; Zhou XL; Yang RL; Zhao ZY
Zhonghua Er Ke Za Zhi; 2016 Dec; 54(12):927-930. PubMed ID: 27938594
[No Abstract] [Full Text] [Related]
48. Newborn screening for inborn errors of metabolism: a systematic review.
Seymour CA; Thomason MJ; Chalmers RA; Addison GM; Bain MD; Cockburn F; Littlejohns P; Lord J; Wilcox AH
Health Technol Assess; 1997; 1(11):i-iv, 1-95. PubMed ID: 9483156
[TBL] [Abstract][Full Text] [Related]
49. Expanded newborn screening by tandem mass spectrometry: the Massachusetts and New England experience.
Marsden D
Southeast Asian J Trop Med Public Health; 2003; 34 Suppl 3():111-4. PubMed ID: 15906712
[TBL] [Abstract][Full Text] [Related]
50. Relationship of octanoylcarnitine concentrations to age at sampling in unaffected newborns screened for medium-chain acyl-CoA dehydrogenase deficiency.
Khalid JM; Oerton J; Besley G; Dalton N; Downing M; Green A; Henderson M; Krywawych S; Wiley V; Wilcken B; Dezateux C;
Clin Chem; 2010 Jun; 56(6):1015-21. PubMed ID: 20413428
[TBL] [Abstract][Full Text] [Related]
51. Synthesis framework estimating prevalence of MCADD and sensitivity of newborn screening programme in the absence of direct evidence.
Leal J; Wordsworth S; Oerton J; Khalid JM; Dezateux C;
J Clin Epidemiol; 2014 Oct; 67(10):1131-8. PubMed ID: 24998633
[TBL] [Abstract][Full Text] [Related]
52. [Expanded newborn screening in the Region of Murcia, Spain. Three-years experience].
Juan-Fita MJ; Egea-Mellado JM; González-Gallego I; Moya-Quiles MR; Fernández-Sánchez A
Med Clin (Barc); 2012 Dec; 139(13):566-71. PubMed ID: 22137990
[TBL] [Abstract][Full Text] [Related]
53. Newborn screening for medium-chain acyl-CoA dehydrogenase deficiency: a global perspective.
Rhead WJ
J Inherit Metab Dis; 2006; 29(2-3):370-7. PubMed ID: 16763904
[TBL] [Abstract][Full Text] [Related]
54. Tandem mass spectrometry screening for very long-chain acyl-CoA dehydrogenase deficiency: the value of second-tier enzyme testing.
Spiekerkoetter U; Haussmann U; Mueller M; ter Veld F; Stehn M; Santer R; Lukacs Z
J Pediatr; 2010 Oct; 157(4):668-73. PubMed ID: 20547398
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and outcome of expanded newborn screening for metabolic diseases--report of 10 years from South-West Germany.
Lindner M; Gramer G; Haege G; Fang-Hoffmann J; Schwab KO; Tacke U; Trefz FK; Mengel E; Wendel U; Leichsenring M; Burgard P; Hoffmann GF
Orphanet J Rare Dis; 2011 Jun; 6():44. PubMed ID: 21689452
[TBL] [Abstract][Full Text] [Related]
56. Screening newborns for inborn errors of metabolism by tandem mass spectrometry.
Wilcken B; Wiley V; Hammond J; Carpenter K
N Engl J Med; 2003 Jun; 348(23):2304-12. PubMed ID: 12788994
[TBL] [Abstract][Full Text] [Related]
57. Biochemical, molecular, and clinical characteristics of children with short chain acyl-CoA dehydrogenase deficiency detected by newborn screening in California.
Gallant NM; Leydiker K; Tang H; Feuchtbaum L; Lorey F; Puckett R; Deignan JL; Neidich J; Dorrani N; Chang E; Barshop BA; Cederbaum SD; Abdenur JE; Wang RY
Mol Genet Metab; 2012 May; 106(1):55-61. PubMed ID: 22424739
[TBL] [Abstract][Full Text] [Related]
58. Targeted metabolomics in the expanded newborn screening for inborn errors of metabolism.
Scolamiero E; Cozzolino C; Albano L; Ansalone A; Caterino M; Corbo G; di Girolamo MG; Di Stefano C; Durante A; Franzese G; Franzese I; Gallo G; Giliberti P; Ingenito L; Ippolito G; Malamisura B; Mazzeo P; Norma A; Ombrone D; Parenti G; Pellecchia S; Pecce R; Pierucci I; Romanelli R; Rossi A; Siano M; Stoduto T; Villani GR; Andria G; Salvatore F; Frisso G; Ruoppolo M
Mol Biosyst; 2015 Jun; 11(6):1525-35. PubMed ID: 25689098
[TBL] [Abstract][Full Text] [Related]
59. Stability of acylcarnitines and free carnitine in dried blood samples: implications for retrospective diagnosis of inborn errors of metabolism and neonatal screening for carnitine transporter deficiency.
Fingerhut R; Ensenauer R; Röschinger W; Arnecke R; Olgemöller B; Roscher AA
Anal Chem; 2009 May; 81(9):3571-5. PubMed ID: 19323528
[TBL] [Abstract][Full Text] [Related]
60. [Medium-chain acyl-CoA dehydrogenase deficiency: neonatal screening and follow-uP].
Tong F; Jiang PP; Yang RL; Huang XL; Zhou XL; Hong F; Qian GL; Zhao ZY; Shu Q
Zhongguo Dang Dai Er Ke Za Zhi; 2019 Jan; 21(1):52-57. PubMed ID: 30675864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
